Atherosclerosis is one of the main complications of diabetes involving multiple causative factors. Dysfunction of the vascular endothelium is a hallmark of most conditions that are associated with both diabetes and atherosclerosis. Although the pathological link between diabetes and atherosclerosis is well-established, better comprehension of the underlying mechanisms is of utmost importance to identify novel potential molecular targets. It is difficult to separate the effects of hyperglycaemia from those of other atherogenic factors: recent evidence shows that they share many common mechanisms, such as endothelial activation and inflammation, mitochondrial oxidative stress, changes in extracellular matrix components and disruption of cellular defence systems. The plausible hypothesis of the 'common soil' between diabetes and atherosclerosis seems to be born from a unique 'ancestor': the nuclear factor kB, a transcription factor able to guide multiple molecular processes. It seems that this master regulator triggers either some hyperglycaemia-induced effects on the endothelial function, or the expression of certain microRNAs (in particular miR-126, -21 and miR-146a-5p) involved in favouring atherosclerosis. Here, we review the latest evidence and proposed mechanisms, aiming to understand the link between diabetes and atherosclerosis.
Introduction
Diabetes as a non-communicable chronic disease (NCD) represents the major cause of loss of productive life in the European Union (EU) and premature mortality, due to a high incidence of cardiovascular complications (cardiovascular diseases (CVDs)). 1 Among the diabetes population, 90% are affected by type 2 diabetes mellitus (T2DM) and 10% by type 1 diabetes mellitus (T1DM). These figures are estimated to be rising worldwide, fuelling an increase in metabolic and vascular complications (CVDs, blindness, amputations of the lower limbs and impaired renal function) with evidence of increased risk of developing diabetes in the general population.
Hyperglycaemia is the characteristic trait of diabetes. More than half of the mortality in diabetes is related to CVD and the increased risk is related to the extent of glycaemic control. It has been reported in the UK Prospective Diabetes Study (UKPDS) 2 and Diabetes Control and Complications Trial (DCCT) clinical trials 3 that tight glycaemic control could reduce the progression of CVD in diabetes, although there have emerged several disagreements on this topic regarding the frequency of hypoglycaemic events. Recently, a cross-sectional Chinese Atherosclerosis Risk Evaluation (CARE-II) study of subjects with or without diabetes, with pre-existing symptoms such as cerebral ischaemic symptoms of anterior circulation and carotid atherosclerosis plaques, has shown that people with diabetes are more likely to have carotid plaque with calcification and lipid-rich necrotic cores than people without diabetes, suggesting that diabetes may lead to development of more severe atherosclerotic lesions. 4 However, the Atherosclerosis Risk in Communities (ARIC) study in 2010 reported a higher incidence of cardiovascular disorders and mortality due to ischaemic cardiopathy also in subjects with no clinical sign of diabetes but having a transitory dys-or hyperglycaemia. 5 Clinical relationships between diabetes and atherosclerosis are well established. The majority of the clinical and experimental data regarding the onset of diabetes complications are associated with atherosclerosis, suggesting that the impact of chronic hyperglycaemia might induce damage on vascular homeostasis, mainly attributable to the endothelium function. Numerous observational studies have found increased levels of the mediators of inflammation, such as C-reactive protein (CRP), interleukin-6 (IL-6), plasminogen activator inhibitor 1 (PAI-1), to name only a few, as major associative findings between diabetes and atherosclerosis. In addition, results have shown that people with diabetes have a high incidence of two or more vessel disease compared with subjects without diabetes. 6 However, in the Insulin Resistance Atherosclerosis Study (IRAS) it has been reported that there is an association of increased atherosclerosis in the internal carotid artery with diabetes, and that the degree of atherosclerosis in newly diagnosed diabetes is higher with respect to normoglycaemic subjects. 7 There is a growth of evidence which also shows a higher prevalence of arteriosclerosis in people with diabetes, characterised by vascular calcification of the media (VCm) and by vascular stiffness (VS), both contributors to the significantly high prevalence of peripheral vascular disease (PVD) with more severe complications and lower extremity amputations. 8, 9 The activation mechanisms driving VCm/VS are different from atherosclerosis due to the induction of different biochemical cascades. Although the acknowledgement of the latter mechanisms is undoubtedly important for future investigations in T2DM, in this article we focus on the link between hyperglycaemia-driven derangements of endothelial function and the silent onset of atherosclerosis, followed by a brief overview on medial calcinosis occurring in diabetes. Furthermore, we discuss the possibility that diabetes and atherosclerosis may have common epigenetic and environmental antecedents, as demonstrated by the evidence of a common 'master' regulating critical aspects of atherosclerotic lesion formation. In this view, under the influence of the diabetes-milieu, microRNA patterns (short RNA molecules able to modulate their target gene expression) might suffer some changes affecting the levels of significant proteins, driving the dysregulation of endothelial functions and promoting or accelerating atherosclerosis. Finally, a fascinating hypothesis regarding the reduced activation of intracellular antioxidant responses that may negatively impact on endothelial functions and on the diabetesassociated atherosclerosis will be presented.
Endothelial dysfunction and inflammation
Dysfunction of the vascular endothelium is a hallmark of most conditions that are associated with both diabetes and atherosclerosis and may result in CVD.
The atherosclerotic phenotype is characterised by intimal thickening with the accumulation of lipids, inflammatory cells and fibrous elements narrowing the arteries by deposition of plaques. 10 Thus, the constituted atheroma is subjected to recruitment and adhesion of leucocytes to the site of the atherosclerotic lesion, triggering inflammatory processes and leading to plaque rupture and eliciting thrombotic phenomena (Figure 1(a) ). It is inferred that biomechanical injury occurs, and hypercholesterolaemia could cause the retention of lipoproteins in the vessel walls which initiates inflammatory responses, and the alteration of blood flow could cause the onset of downstream atherosclerotic processes.
Different phases of the atherosclerotic lesion progression are regulated by different mechanisms: diabetes accelerates cardiovascular events by inducing an accelerated formation of the atherosclerotic lesions. Elevated glucose might play an important role in this progression, because glucose may act in concert with lipids levels, determining a real cross-talk between signalling events induced by glucose and lipids. Many of the signalling pathways induced by glucose are mediated by bioactive lipids. 11 High glucose regulates arachidonic acid metabolism, inducing cyclooxygenase-2 (COX2) expression with an increased release of thromboxane-B2 and prostaglandin-E2; on the other hand, high glucose might induce expression of 12/15 lipoxygenase and increases levels of the 12/15 lipoxygenase product 12(S)HETE in aortic endothelial cells (ECs), 12 that has been found to stimulate monocyte adhesion to ECs. 13 In this context, oxidised low-density lipoprotein (LDL) and oxidised phospholipids also mediate their effects in ECs through increased arachidonic acid release and subsequent stimulation of the lipoxygenase pathway; it is interesting that elevated glucose can cause LDL-oxidation and that reactive carbonyl species, advanced glycated end products (AGEs), and advanced lipoxidation end products (ALEs) might also contribute to modifying the lipids in the lipoproteins. 14 The mechanisms linking diabetes and atherosclerosis have not been directly elucidated, but several hypotheses can be suggested. The critical processes responsible for endothelial activation in vascular damage and atherogenesis could be explained by the fine-tuned regulation of several genes and transcription factors, such as nuclear factor kB (NF-kB), and molecules such as AGEs, able to modify the components of the extracellular matrix (ECM). Activation of the receptor for advanced glycation end products (RAGE) in diabetes vasculature is considered to be a key mediator of atherogenesis. 15 Numerous experimental studies have attempted to evaluate the role of high glucose on the cells of the artery wall, including ECs. In this view, it has been proposed that high glucose might activate several physiological, functional and metabolic alterations such as changes in nitric oxide (NO) bioavailability, generation of oxidative stress (OxS), changes in haemodynamics, increasing cellular senescence.
At the basis of these alterations, NF-kB seems to be involved as the mediator of inflammation represents an entry point for metabolic responses. In vascular ECs, the pleiotropic transcription factor NF-kB during hyperglycaemia might be dependent on activation of the family of guanosine triphosphate (GTP)-ases, which leads to the activation of several inflammatory mediators (tumour necrosis factor (TNF)a, IL-1B, IL-6, protein kinase C (PKC)), including adhesion molecules (cellular adhesion molecule (CAM)) that facilitate monocyte and T-cells adhesion to ECs.
In response to biochemical and biomechanical stimuli, atherosclerotic lesion formation occurs in a background of inflamed vessels, due to an altered shear stress, in which hyperglycaemia plays a key role. The functional properties of ECs for regulating NO bioavailability are important for normal endothelial function. Atherosclerosis preferentially develops at arterial branches in which the blood flow is disturbed, imposing low and oscillatory shear stress. It is well established that hyperglycaemia exacerbates the impairment of the haemodynamic forces, particularly shear stress that generally downregulates NO and causes alterations in endothelial phenotype. The interaction between blood flow and the endothelium is a result of the modulation of endothelium-derived relaxing factors, where NO is believed to be one of these factors, but also includes the mechano-sensing of shear forces that are exerted by blood flow itself. This sensing enables the endothelium to enforce vasoregulation through the production of vasodilators such as NO and prostacyclin (PGI 2 ) and vasoconstrictors such as endothelin (ET). Sulistyowati et al. 16 demonstrated that high glucose disturbs normal shear-stress-inducing changes in morphology and density of EC, deranging vascular permeability and the recruitment of leucocytes for inflammatory responses.
In particular, the aforementioned study showed that hyperglycaemia could have important implications in the activation of ECs: high glucose, decreasing endothelial nitric oxide synthase (eNOS) activation and decreased shear-induced alignment might be indicative of impaired mechanotransduction. A fundamental step in NO production by ECs is the phosphorylation of eNOS by several serine/threonine kinases acting in an orchestrated manner in the insulin-signalling pathway. Hyperglycaemia disrupts the endothelial equilibrium, compromising also the binding with the insulin receptor, activating a transduction way in favour of pro-atherogenic effects instead of antiatherogenic responses. Indeed, it is known that the insulin receptor can activate the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/eNOS pathway in the endothelium: the phosphorylation of eNOS at Ser1177, activated by AKT kinase, leads to the production of NO; conversely, it also activates the phosphorylation of Src-homology 2 domain containing (SHC) transforming protein , which leads to the activation of the mitogen-activated protein kinase (MAPK) pathway, resulting in increased ET-1 expression and mitogenic effects. 17 Under high levels of glucose and insulin-stimulated cells, the pro-atherogenic pathway seems to be more prone to activation. In addition, several atheroprotective properties have been attributed to proteoglycans based on their capacity to inhibit monocyte binding to the subendothelial region. 18 In diabetes-milieu there has been shown to be a reduced amount of proteoglycans, 19 suggesting an increased exposition of EC to adhesion molecules, such as the vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), which are required for the adhesion of leucocytes to the endothelial surface to initiate the recruitment of factors for inflammation. 20 Inflammation in the blood vessels is the key event driving towards atherosclerosis, and diabetes confers the worse phenotype; indeed, the circulating markers of inflammation, as well as monocyte gene expression of proinflammatory mediators, are elevated in diabetes. 21 The mechanistic description of the pathogenesis of this phenomenon is not completely clear. Initially, the activation of ECs is fundamental in triggering the pathological process increasing vascular permeability, and needs the recruitment of specific cells such as monocytes/macrophages and mast cells that are able to detect the presence of the dangerous insult (such as oxidised LDL), to allow for releasing pro-inflammatory cytokines, chemokines and vasoactive mediators in order to amplify the immune response.
Elevated glucose and certain lipids, such as modified lipoprotein particles or saturated fatty acids, might each contribute to enhancing inflammation. Glucose alone can affect monocyte/macrophage activation in vitro. Thus, monocytes grown in high levels of glucose conditions show evidence of increased expression of the cytokines, IL-1b and IL-6. Monocytes attracted into the endothelium give rise to the extraordinary conversion of foam cells in the accumulation of lipids, forming the atherosclerotic plaque.
Many pharmacological strategies can delay the progression of different phases of the atherosclerotic lesion (Table 1) . A class of lipid-lowering agents, such as hydroxymethylglutaril-coenzyme A (HMG-CoA)reductase inhibitors (statins), is used in primary and secondary prevention for atherosclerosis, with protective effects which are attributable to a reduction in cholesterol levels. Their pleiotropic effects range from ameliorating the prognosis of and reducing transient myocardial ischaemia in patients at risk, ameliorating endothelial function in stable and unstable coronary artery disease, 22 to marked anti-inflammatory effects. Despite these beneficial effects, conflicting results are reported about statins in interfering with insulin signalling transduction pathways. However, the ability of statins to reduce major cardiovascular events and mortality outweighs this risk, and no change in clinical practice is currently recommended. 23, 24 Besides these benefits in reducing cardiovascular mortality and reducing hyperlipidaemia (the latter stimulating for vascular calcification (VC)), a paradoxical effect of statins has been reported in inducing calcification in human subjects. 25 This finding raises important questions about the therapeutic management of patients.
VCm and diabetes
VC is a severe, not reversible patho-phenotype highly prevalent in subjects with atherosclerosis, diabetes and chronic kidney disease (CKD), associated with vascular dysfunction. VC is subgrouped into intimal (VCi), typical in atherosclerosis, and medial calcification (VCm) that may occur in the absence of atherosclerosis. Subjects with diabetes are strongly prone to promote VC, 8 with a loss of elasticity of smooth muscle cells (SMCs) and elastic membrane, increased fibrosis and arterial stiffness (AR): through a combination of damaging factors such as hyperglycaemia, deposits of hydroxyapatite crystals (calcium or phosphate) and elastin degradation products, coupled with transforming growth factor (TGF)-beta 1 commonly elevated in diabetes, the osteogenic markers as alkaline phosphatase (ALP), osteocalcin and Runt-related transcription factor-2 (Runx2) in vascular cells became elevated triggering a mineralization process. In this context ( Figure  1(b) ), a loss of inhibitors of matrix Gla (gamma-carboxyglutamate) protein (MGP) and high levels of pyrophosphate promote medial calcification in mice; 26 also osteopontin, collagen type-1, osteoprotegerin, bone morphogenic protein-2 (BMP) and osteocalcin are critical in this process.
VCm and VCi often coexist, overlap and add up in advanced atherosclerosis lesions leading to the occurrence of more severe complications. In fact, distinct biochemical cascades and inflammatory components in atherosclerotic plaques promote osteogenic differentiation and, occasionally, even ossification, by releasing pro-inflammatory cytokines that are different from the initiation of the VCm. The latter seems to be rare in the coronary and carotid vessels, but common in media and SMCs in peripheral arteries, exposing people with diabetes to increased risk of dementia, stroke, limb ischaemia, renal insufficiency and lower extremity amputation. A better understanding of the different initiating mechanisms, having different pathogenesis and clinical consequences, could allow for the identification of specific therapies for specific patients.
Oxidative stress
Hyperglycaemia-derived oxidative stress is the main pathogenic mechanism of diabetes complications. Beside the inflammatory changes, intracellular hyperglycaemia causes tissue damage by mechanisms that can be traced back to biochemical pathways such as (a) intracellular PKC overactivity, in which its activation via NF-kB has been implicated in the increase of superoxide anions and thus in the reduction of NO and enhanced permeability by vascular endothelial growth factor (VEGF); (b) increased polyol pathway flux in which the consumption of reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) could increase the redox stress and exacerbate intracellular oxidative stress: the latter could facilitate LDL oxidation in vitro; (c) increased flux through the hexosamine pathway, where fructose-6-phosphate is diverted from normal glycolysis to provide the substrate for the fructose 6-phosphate aminotransferase (GFAT) responsible for TGF-beta transcription and triggering fibrotic processes; and (d) generation of AGEs, and other glycated compounds, derived both from glucose and fatty acid oxidation in arterial ECs. 27 AGEs can damage cells by modifying proteins of the ECM with consequent functional alteration, multiple interactions of ECM components and trigger signal transduction via reactive oxygen species (ROS) generation. An example of matrix modification by AGEs is the alteration of the glomerular basement membrane inducing an increased permeability to albumin, 28 pathological changes in ECs inducing activation of pro-atherogenic and pro-thrombotic genes. 29 AGEs ultimately could interfere in reverse cholesterol transport by inhibiting the selective uptake of high-density lipoprotein (HDL) ester as well as cholesterol efflux from peripheral cells to HDL. It is thought that HDL glycation in diabetes might be the cause of HDL dysfunction and of the loss of its atheroprotective effects. It seems that the AGE/RAGE axis also promotes VC, Table 1 . Pharmacological treatment options in diabetes management to reduce the impact of atherosclerosis and cardiovascular disease (CVD). exacerbating the already existing atherosclerotic damage to more severe lesions. VC mainly occurs on vascular smooth muscle cells (VSMCs) by activation of osteogenic programmes, such as promoting the increase of ALP and Runx2, determinant for an osteoblast-like phenotype constitution. 30 Previous studies have demonstrated the relationship between the formation of carotid plaques in subjects with diabetes due to the elevation of the glucose metabolism-induced glycosylation of N-acetylglucosamine (O-GlcNac) and the stimulation of osteogenesis regulator Runx2. 31 As reported by many studies, hyperglycaemia directly influences the overproduction of ROS. In particular, the overproduction of superoxide anions from the mitochondria could account for the aforementioned pathways. Indeed, specific inhibitors of each pathway ameliorate diabetes-induced abnormalities in cell culture.
Drug class Effects
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Recent data have disclosed some alterations observed in the NF-kB activation under hyperglycaemia-induced oxidative stress. It is worthy of note that ROS might affect the pleiotropic transcription factor NF-kB by activating or repressing it, having various inhibitory or stimulatory roles. ROS drives NF-kB signalling by reacting with cysteines at the catalytic site, promoting oxidation and irreversible inactivation of several phosphatases. A specific cysteine of the NF-kB subunit p50, Cys-62, is especially sensitive to oxidation and triggers to the inhibition of the DNA-binding to specific regions (see review). 32 It is still a matter of debate whether ROS might also activate NF-kB since their relative steady-state concentrations strongly depend on cellular antioxidant defences. On the other hand, some studies have also highlighted that NF-kB can be regulated by peroxynitrite, which is a reactive nitrogen species. 33 The activity of the antioxidant defensive mechanisms carried out by a plethora of antioxidant and phase II detoxification genes guided by nuclear factor erythroid-derived 2-like (NRF2; NFE2L2) activation, e.g. heme-monoxygenase-1 (HMOX-1), NADPH-quinoneoxidoreductase-1 (NQO1) among others, provide protection against oxidative stress. Recently, it has been described that, although the enzymes catalase (CAT), superoxide dismutases (SODs) and glutathione peroxidase (GPx) are deputed to protect cells against the damage, the antioxidant responses in people with diabetes with complications are inactivated. 34 These findings are supported also by cellular studies, in which the role of epigenetics in regulating the defective antioxidant response in the diabetes-milieu has emerged. 35, 36 In addition, animal studies have shown that the deficiency of GPx-1 accelerates diabetes-associated atherosclerosis in ApoE-deficient mice (ApoE -/-) via the up-regulation of the proinflammatory and fibrotic pathway. 37 
Epigenetics as the missing link between diabetes and atherosclerosis
In recent years, epigenetics has emerged as an important form of biological regulation of gene expression and might be the major contributor to the appearance of diabetes and CVD, their onset being closely influenced by environmental and lifestyle modifications. Along with DNA methylation (DNA-me), histone modifications and RNA-based mechanisms as the major epigenetic controllers, small non-coding RNAs known as microRNAs (miRNAs or miRs) have additional implications in many diseases. There is increasing evidence supporting the role of miRNAs with a significant role in the modulation of the expression pattern of genes involved in many diseases, including diabetes and atherosclerosis. miRNAs, as endogenous molecules, are initially recognised by complementary miRNA recognition elements (MREs) throughout mRNA sequences, in the 3 0 -and 5 0 -untranslated regions (UTRs). miRNAs can be found in different genomic regions: (a) in introns of protein-coding genes, (b) in exons and introns of non-coding genes and even (c) in the 3 0 -UTR of protein-coding genes. These localizations provide a further dynamic regulation of a network of biological processes, e.g. the regulation mechanism of the splicing machinery, that would be able to influence miRNA transcription toward pathological status. Since miRNAs are able to silence protein expression, their dysregulation can affect the expression of hundreds of mRNAs and proteins.
miRNAs have been proposed as surrogate markers of the prediabetes state, 38, 39 diabetes and cardiovascular complications, 40 being detectable in a stable form in blood circulation and biological fluids. Many studies have revised the involvement of miRNAs in the vascular complications of diabetes 29 as well as in atherosclerosis, 41 determining a branch of investigation deserving special attention due to potential diagnostic and therapeutic implications. 'A number of miRNAs associated with atherosclerosis in in-vitro studies (such as miR-10a, -126, -145, -146a/b, -185, -21, and -326) are expressed in atherosclerotic plaques in a similar pattern to that found in the experimental diabetes-milieu. Along the many miRNAs, such as the endothelial miR-126 which affect both vascular dysfunction and inflammatory state, 42 it is believed that the activation of miR-21 may be a critical event linking diabetes and the development of atherosclerosis. Indeed, it may trigger the endothelial activation influencing the formation of foam cells, adhesion of circulating monocytes, macrophage apoptosis and the clearance capacity of phagocytes. 43 In the diabetes-milieu, the miR-21 function appears once again in the inhibition mechanisms of the antioxidant response, silencing the major mitochondrial antioxidant enzyme SOD2, via the Krev interaction trapped protein (KRIT)-1 regulator of ROS homeostasis. 36 In addition, the importance of this miRNA is evidenced by the study of Zhou et al. 44 in which the expression of miR-21, induced itself by haemodynamic forces such as e.g. oscillatory shear stress (OSS), contribute to promoting the pro-inflammatory responses in human umbilical vein endothelial cells (HUVECs) via an increased binding of c-Jun to the promoter region of miR-21. 44 However, in a hyperglycaemic model, a wound-healing chromatin immunoprecipitation (ChIP)-assay revealed binding of NF-kB to the miR-21 promoter initiating the transcription of the miRNA whose expression is also increased in the skin of diabetes patients. 45 It is thought that miR-21 is able to act in a feedback loop in which NF-kB activates miR-21 that in turn is able to silence NF-kB ( Figure 2 ). Beside miR-21, many miRs could be involved in the elevated glucose-induced atherothrombotic phenomenon: miR-146a-5p was identified as a negative regulator of NF-kB. 46 The reduction in miR-146a expression could lead to less efficient inhibition of target genes involved in the NF-kB and other cytokine production and signalling pathways. In addition, interleukin-1 receptorassociated kinase (IRAK)1, TNF receptor-associated factor 6 (TRAF6) and IRAK2 are addressed as own targets 47 indicating the contribution of this miR to attenuating inflammatory cytokine production and the role in a proinflammatory state. In many diabetesrelated studies, in animals and humans, a high level of glucose was able to decrease cellular miR-146a-5p levels impairing its negative feedback on NF-kB signalling observed during TNF-a, lipopolysaccharide (LPS), IL-1beta, phorbol 12-myristate 13-acetate (PMA), and ox-LDL stresses. 46 The study of Wang et al. 48 highlighted the effect of downregulated miR-146a-5p on the upregulation of NADPH oxidase 4 (Nox4) expression in aortic ECs under high glucose and thrombin levels; Nox4 is expressed in resting ECs and generally increasing levels provide the ability to generate ROS. It appears that the downregulation of miR-146a-5p fails to help to knock down the levels of Nox4 and its detrimental effect stimulating ROS, thus enhancing the inflammatory phenotype, senescence 49 and apoptosis. 50 In addition, miR-146a-5p negatively modulates IL-6, 51 the latter contributing to both atherosclerotic plaques growth and destabilization.
Recently, a study identified some miRs common in diabetes, CKD and coronary artery disease (CAD), with Figure 2 . MicroRNA orchestration of nuclear factor kB (NF-kB) signalling in endothelial dysfunction. NF-kB, a transcription factor that is essential for inflammatory responses, is one of the most important molecules linking many diseases and its activity is tightly regulated by several mechanisms. In endothelial cells, miRNAs repress the expression of genes involved in NF-kB signalling. The high glucose-induced miR-21 exerts a feedback loop on NF-kB: their cross-talk might be essential also in macrophage activity leading to advanced endothelial lesions. In addition to miR-21, the modulation of miR-146a by high glucose can promote the NF-kB expression that triggers endothelial dysfunction and inflammation. AGE: advanced glycated end product; CRP: C-reactive protein; eNOS: endothelial nitric oxide synthase; GPx1: glutathione peroxidase-1; NO: nitric oxide; O 2 -: superoxide anion; PKC: protein kinase C; ROS: reactive oxygen species; SOD2: superoxide dismutase 2. a high prevalence of calcification: miR-126, miR-21 and miR-146a were common among the aforementioned diseases having a regulatory role for VCm and the transdifferentiation of SMCs to osteogenic-like cells. 52 
Conclusion
The continued increase in the prevalence of diabetes in the general population is predicted to result in a higher incidence of CVDs. Hyperglycaemia exerts many of its cellular effects driving toward endothelial dysfunction and enhanced inflammation. Processes related to both diabetes and atherosclerosis have been shown to similarly affect the common antecedents such as the activation of transcription factor NF-kB, which in turn appear to be regulated by miRNAs. For example, mir-126, -146a and -21 are expressed similarly in several tissues and cell types related to atherosclerosis, providing evidence for an association between diabetes and the onset/ progression of CVDs. The idea of the role of the miRs in the preventative or therapeutic intervention approach is highly appealing because of their high regulatory/inhibitory activity. For the treatment of atherosclerosis, numerous approaches have been carried out with the use of anti-miRs technologies, from in-vitro to mouse models of cardiac disease, showing that, for example, the anti-miR-21 approach (from Regulus Therapeutics, San Diego, CA) ameliorates cardiac dysfunction and executes an antifibrotic response. Only one anti-miRs approach from the same company, is run in a nonhuman primate study using African Green monkeys, in which the inhibition of another important miR (that is not the topic of this review), miR-33a/b, is able to regulate cholesterol and fatty acid homeostasis with an increase of HDL and without significant side effects. 53 In the near future it will become clear if the miR-technology will have the ability to compete with, and perhaps more effectively, the selective protein inhibitors currently used in therapeutic interventions.
